SCHEMBL741537

SCHEMBL741537

COC(=O)c1ccc(-c2ccncc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 1/20 0.57
CA1 P00915 4/20 0.56
CA2 P00918 4/20 0.56
CA12 O43570 3/20 0.56
CA9 Q16790 3/20 0.56
CA14 Q9ULX7 3/20 0.56
RAF1 P04049 1/20 0.56
TDP1 Q9NUW8 1/20 0.55
CA7 P43166 1/20 0.55
MAPK13 O15264 1/20 0.55
ALOX5 P09917 1/20 0.55
GCGR P47871 1/20 0.55
MAPK12 P53778 1/20 0.55
MAPK11 Q15759 1/20 0.55
MAPK14 Q16539 1/20 0.55
IKBKE Q14164 1/20 0.53
TBK1 Q9UHD2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13019478 1.00 HDAC1 (0.58) HDAC1HDAC6ALDH1A1KDM4ECA1
SCHEMBL8506592 0.88 MEN1 (0.55) ALDH1A1KDM4ECA1CA2CA12
Methyl Isonicotinate SCHEMBL180574 0.87 CYP1A2 (0.60) ALDH1A1KDM4ECA1CA2CA12
Methyl Isonicotinate SCHEMBL820082 0.87 CYP1A2 (0.60) ALDH1A1KDM4ECA1CA2CA12
SCHEMBL19387238 0.87 CA1 (0.70) ALDH1A1KDM4ECA1CA2CA12
Biphenyl Dimethyl Dicarboxylate SCHEMBL68521 0.87 CA1 (0.70) ALDH1A1KDM4ECA1CA2CA12
Methyl Isonicotinate SCHEMBL9217491 0.85 LMNA (0.58) ALDH1A1KDM4ECA1CA2CA12
Methyl Isonicotinate SCHEMBL9213497 0.85 LMNA (0.58) ALDH1A1KDM4ECA1CA2CA12
Methyl Isonicotinate SCHEMBL29827431 0.85 LMNA (0.58) ALDH1A1KDM4ECA1CA2CA12
Biphenyl Dimethyl Dicarboxylate SCHEMBL2890577 0.85 CA1 (0.67) ALDH1A1KDM4ECA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110938076-B Pyrrolopyrimidines as TLR7 agonists 正大天晴药业集团股份有限公司 2021-08-10 CN disclosed
CN-112898308-A Pyrrolopyrimidines as TLR7 agonists 正大天晴药业集团股份有限公司 2021-06-04 CN disclosed
EP-3190113-B1 PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-05-19 EP disclosed
EP-3190113-B1 PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-05-19 EP disclosed
CN-110759916-B Pyrrolopyrimidines as TLR7 agonists 正大天晴药业集团股份有限公司 2021-02-19 CN disclosed
CN-110938076-A Pyrrolopyrimidines as TLR7 agonists 正大天晴药业集团股份有限公司 2020-03-31 CN disclosed
US-10555949-B2 Pyrrolopyrimidine compounds used as TLR7 agonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-02-11 US disclosed
US-10555949-B2 Pyrrolopyrimidine compounds used as TLR7 agonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-02-11 US disclosed
CN-110759916-A Pyrrolopyrimidines as TLR7 agonists 正大天晴药业集团股份有限公司 2020-02-07 CN disclosed
CN-106661034-B Pyrrolopyrimidines as TLR7 agonists 正大天晴药业集团股份有限公司 2019-11-29 CN disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 EP disclosed
EP-1254124-A1 DIPEPTIDE NITRILE CATHPSIN K INHIBITORS Novartis AG (CH) 2002-11-06 EP disclosed
US-6323227-B1 PRODRUGS AVENTIS PHARMACEUTICALS PRODUCTS INC. 2001-11-27 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
US-20010016207-A1 Dipeptide nitrile cathepsin K inhibitors NOVARTIS AG (CH) 2001-08-23 US disclosed
WO-2001058886-A1 DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS NOVARTIS AG (CH) 2001-08-16 WO disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed
CN-1236358-A Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides RHONE POULENC RORER PHARMA (US) 1999-11-24 CN disclosed
EP-0931060-A1 SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-28 EP disclosed
WO-1999000356-A1 SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010016207-A1 Dipeptide nitrile cathepsin K inhibitors CTSK, CTSC, CTSS HDAC1 658/4885HDAC6 987/4885ALDH1A1 2798/4885
US-10555949-B2 Pyrrolopyrimidine compounds used as TLR7 agonist TLR7, TLR9, TLR1 HDAC1 1632/4885HDAC6 593/4885ALDH1A1 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.